Hangzhou Jiuyuan Gene Engineering Co. Ltd. Announces NMPA Approval for Jilixin, Enhancing Treatment Options for Thrombocytopenia Patients

Reuters

2025/07/03

Hangzhou <a href="https://laohu8.com/S/02566">Jiuyuan Gene</a> Engineering Co. Ltd. Announces NMPA Approval for Jilixin, Enhancing Treatment Options for Thrombocytopenia Patients

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has announced that its new drug, Jilixin (avatrombopag), has received marketing approval from the National Medical Products Administration (NMPA) of China. This approval allows the use of Jilixin for adult patients with thrombocytopenia induced by chronic liver diseases and those with chronic primary immune thrombocytopenia $(ITP)$ who have not responded adequately to previous treatments. Jilixin is a new-generation oral thrombopoietin receptor agonist that increases platelet production, offering a more convenient treatment option without the need for frequent injections. The drug's inclusion in the Class B category of the National Medical Insurance Catalogue further broadens its accessibility. This development marks a significant expansion in Hangzhou Jiuyuan's product offerings in the treatment of thrombocytopenia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief on July 03, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2548803656"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548803656\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548803656?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-03 18:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548803656","market":"fut","top_or_hot":-1,"title":"Hangzhou Jiuyuan Gene Engineering Co. Ltd. Announces NMPA Approval for Jilixin, Enhancing Treatment Options for Thrombocytopenia Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hangzhou <a href=\"https://laohu8.com/S/02566\">Jiuyuan Gene</a> Engineering Co. Ltd. Announces NMPA Approval for Jilixin, Enhancing Treatment Options for Thrombocytopenia Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has announced that its new drug, Jilixin (avatrombopag), has received marketing approval from the National Medical Products Administration (NMPA) of China. This approval allows the use of Jilixin for adult patients with thrombocytopenia induced by chronic liver diseases and those with chronic primary immune thrombocytopenia <a href=\"https://laohu8.com/S/ITP\">$(ITP)$</a> who have not responded adequately to previous treatments. Jilixin is a new-generation oral thrombopoietin receptor agonist that increases platelet production, offering a more convenient treatment option without the need for frequent injections. The drug's inclusion in the Class B category of the National Medical Insurance Catalogue further broadens its accessibility. This development marks a significant expansion in Hangzhou Jiuyuan's product offerings in the treatment of thrombocytopenia.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief on July 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hangzhou Jiuyuan Gene Engineering Co. Ltd. Announces NMPA Approval for Jilixin, Enhancing Treatment Options for Thrombocytopenia Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHangzhou Jiuyuan Gene Engineering Co. Ltd. Announces NMPA Approval for Jilixin, Enhancing Treatment Options for Thrombocytopenia Patients\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-03 18:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hangzhou <a href=\"https://laohu8.com/S/02566\">Jiuyuan Gene</a> Engineering Co. Ltd. Announces NMPA Approval for Jilixin, Enhancing Treatment Options for Thrombocytopenia Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has announced that its new drug, Jilixin (avatrombopag), has received marketing approval from the National Medical Products Administration (NMPA) of China. This approval allows the use of Jilixin for adult patients with thrombocytopenia induced by chronic liver diseases and those with chronic primary immune thrombocytopenia <a href=\"https://laohu8.com/S/ITP\">$(ITP)$</a> who have not responded adequately to previous treatments. Jilixin is a new-generation oral thrombopoietin receptor agonist that increases platelet production, offering a more convenient treatment option without the need for frequent injections. The drug's inclusion in the Class B category of the National Medical Insurance Catalogue further broadens its accessibility. This development marks a significant expansion in Hangzhou Jiuyuan's product offerings in the treatment of thrombocytopenia.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief on July 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDL1bx1Y0:1","article_id":"2548803656","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548803656","pubTimestamp":1751537948,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hangzhou Jiuyuan Gene Engineering Co. Ltd. Announces NMPA Approval for Jilixin, Enhancing Treatment Options for Thrombocytopenia Patients. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief on July 03, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02566":"九源基因"},"translate_title":"杭州九源基因工程有限公司宣布吉利欣获NMPA批准，增强血小板减少症患者的治疗选择","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":0.9},"content_text":"Hangzhou Jiuyuan Gene Engineering Co. Ltd. Announces NMPA Approval for Jilixin, Enhancing Treatment Options for Thrombocytopenia Patients\n    \n\n        Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has announced that its new drug, Jilixin (avatrombopag), has received marketing approval from the National Medical Products Administration (NMPA) of China. This approval allows the use of Jilixin for adult patients with thrombocytopenia induced by chronic liver diseases and those with chronic primary immune thrombocytopenia $(ITP)$ who have not responded adequately to previous treatments. Jilixin is a new-generation oral thrombopoietin receptor agonist that increases platelet production, offering a more convenient treatment option without the need for frequent injections. The drug's inclusion in the Class B category of the National Medical Insurance Catalogue further broadens its accessibility. This development marks a significant expansion in Hangzhou Jiuyuan's product offerings in the treatment of thrombocytopenia.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief on July 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}